Toad Trade Externalizes Psychedelic Harms

The commercialization of 5‑MeO‑DMT (toad secretions) creates a supply chain that pushes violence, legal risk, ecological damage, and cultural appropriation onto impoverished local collectors and wild animal populations while buyers foreground therapeutic or spiritual benefits. That supply‑side dynamic should be treated as a policy problem distinct from clinical research into the molecule. — This reframes psychedelics policy from a narrow clinical/regulatory debate to a cross‑cutting supply‑chain issue implicating conservation, criminal justice, indigenous rights, and medical safety.